2024-10-31 15:07:00
They are the talk of the town, the new drugs against obesity and diabetes. Wegovy, Ozempic, Mounjaro… these GLP-1 analogues which affect satiety, show spectacular results in weight loss. To the point of seeing their demand jump and putting pressure on supply.
To meet demand, the two laboratories have increased their investment announcements. They focused on two essential stages: the manufacturing of active ingredients and the filling and packaging operations (in the form of self-injectable pens). These projects will be carried out over the coming years. While the pharmaceutical industry tends to subcontract, Lilly and Novo Nordisk have chosen to internalize the production of these drugs as much as possible. And the two laboratories favor their country of origin, Denmark for Novo Nordisk and the United States for Lilly.
Discover in our interactive map the major investment announcements in the production of new drugs against diabetes and obesity.
Novo Nordisk: a massive investment in Europe and a takeover that gets people talking
The Danish laboratory has signed an extraordinary industrial investment in France in pharma, injecting more than 2 billion euros into its Chartres site. Novo Nordisk has also strengthened its Danish roots by strengthening its active ingredient production sites. The Koge and Kalundborg factories will change size. Novo Nordisk is not forgetting the strategic American market, by planning to build a new facility in Clayton, North Carolina, dedicated to filling. But the investment that will undoubtedly have caused the most talk is the purchase of the American CDMO Catalent. A not ordinary operation in the pharmaceutical industry, the acquisition of a subcontracting giant and three of its sites, which will however still have to pass the validation stage by the American Agency responsible for enforcing the law to competition.
Lilly: investment records on American soil
Lilly has made the United States the heart of its global production. The laboratory has announced several times to strengthen investment on its Lebanon site, not yet in service. Europe is also benefiting from the dynamic. In Germany, Lilly will launch a new factory, the result of an investment of 2.5 billion euros. In Ireland, its Kinsale facility will benefit from a budget of $800 million. If the amount is more modest, Lilly’s Alsatian site in Fegersheim will contribute to increasing the overall offer thanks to an investment of €160 million.
Selected for you
1730428521
#investment #map #Lilly #Novo #Nordisk #boost #production #drugs #obesity
**Interview with Dr. Emily Robinson, Pharmaceutical Industry Expert and Analyst**
**Editor:** Thank you for joining us today, Dr. Robinson. With the recent announcements of significant investments by Novo Nordisk and Lilly in the production of GLP-1 analogues like Wegovy and Ozempic, how do you see these developments impacting the obesity and diabetes treatment landscape?
**Dr. Robinson:** Thank you for having me! The surge in investments from these companies signifies a pivotal moment in the fight against obesity and diabetes. These GLP-1 analogues have shown incredible results in weight loss and blood sugar control, which could transform treatment protocols. By building more manufacturing facilities and increasing production capabilities, both companies are responding to the high demand while also ensuring that they maintain quality and accessibility for patients.
**Editor:** Novo Nordisk’s investment of over 2 billion euros in France and its acquisition of Catalent has certainly caught attention. What does this indicate about the company’s strategy moving forward?
**Dr. Robinson:** It’s quite a bold move for Novo Nordisk. By investing heavily in their European manufacturing capabilities and acquiring Catalent, they’re not only enhancing their production capacity but also vertically integrating their supply chain. This strategy allows them to exert more control over the manufacturing process and ensure that they can meet market demand promptly. Additionally, expanding operations in France and strengthening their presence in the U.S. reflects their commitment to being at the forefront of diabetes and obesity treatment on a global scale.
**Editor:** Lilly has also made significant strides, focusing on its U.S. facilities with substantial investments like the 2.5 billion euros in Germany. How does this reflect on the company’s long-term vision?
**Dr. Robinson:** Lilly’s focus on the U.S. as a central hub for production shows a clear strategic direction. The substantial investments in their new factory in Germany and expansions in Ireland indicate that they are not only preparing for current demand but also anticipating future growth in the obesity treatment market. This could position Lilly as a leading player in providing essential therapies, especially as public health challenges related to obesity and diabetes continue to grow globally.
**Editor:** Lastly, with increasing demand and investments in the GLP-1 market, what challenges do you foresee for these companies moving forward?
**Dr. Robinson:** One of the main challenges will be scalability while maintaining quality standards. As production ramps up, ensuring that they can consistently deliver safe and effective products will be crucial. Additionally, regulatory scrutiny will be high, especially with acquisitions like Novo Nordisk’s Catalent purchase—competition laws will need to be navigated carefully. Furthermore, as more players enter this lucrative market, these companies will need to innovate continuously to differentiate their offerings and mitigate pricing pressures.
**Editor:** Thank you, Dr. Robinson, for your insights. This certainly is an exciting time for the pharmaceutical industry, particularly in the realm of obesity and diabetes treatments.
**Dr. Robinson:** Thank you! It’s a pleasure to discuss these developments, and I’m looking forward to seeing how things evolve in the near future.
